Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

Br J Haematol. 2012 Apr;157(2):254-6. doi: 10.1111/j.1365-2141.2011.08939.x. Epub 2011 Nov 11.

Authors

Kazuma Ohyashiki, Sei-ichiro Katagiri, Tetsuzo Tauchi, Junko H Ohyashiki, Yasuhiro Maeda, Itaru Matsumura, Tai-ichi Kyo

PMID: 22077498
DOI: 10.1111/j.1365-2141.2011.08939.x

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / administration & dosage*
Benzamides
CD3 Complex / blood
CD3 Complex / immunology*
CD8 Antigens / blood
CD8 Antigens / immunology*
CD8-Positive T-Lymphocytes / immunology*
CD8-Positive T-Lymphocytes / metabolism
Female
Humans
Imatinib Mesylate
Killer Cells, Natural / immunology*
Killer Cells, Natural / metabolism
L-Selectin / blood
L-Selectin / immunology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
Lymphocyte Count
Male
Piperazines / administration & dosage*
Pyrimidines / administration & dosage*
Remission Induction

Substances

Antineoplastic Agents
Benzamides
CD3 Complex
CD8 Antigens
Piperazines
Pyrimidines
L-Selectin
Imatinib Mesylate